57 related articles for article (PubMed ID: 38650367)
21. Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.
Roseweir AK; Park JH; Hoorn ST; Powell AG; Aherne S; Roxburgh CS; McMillan DC; Horgan PG; Ryan E; Sheahan K; Vermeulen L; Paul J; Harkin A; Graham J; Sansom O; Church DN; Tomlinson I; Saunders M; Iveson TJ; Edwards J
J Pathol Clin Res; 2020 Oct; 6(4):283-296. PubMed ID: 32401426
[TBL] [Abstract][Full Text] [Related]
22. Cetuximab enhances the efficiency of irinotecan through simultaneously inhibiting the MAPK signaling and ABCG2 in colorectal cancer cells.
Ge XJ; Jiang JY; Wang M; Li MY; Zheng LM; Feng ZX; Liu L
Pathol Res Pract; 2020 Feb; 216(2):152798. PubMed ID: 31889589
[TBL] [Abstract][Full Text] [Related]
23. The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer.
van Wyk HC; Roseweir A; Alexander P; Park JH; Horgan PG; McMillan DC; Edwards J
Ann Surg Oncol; 2019 Dec; 26(13):4397-4404. PubMed ID: 31605345
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells.
Sakata J; Utsumi F; Suzuki S; Niimi K; Yamamoto E; Shibata K; Senga T; Kikkawa F; Kajiyama H
Oncotarget; 2017 Nov; 8(59):99482-99494. PubMed ID: 29245917
[TBL] [Abstract][Full Text] [Related]
25. Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy.
Hansen TF; Kjær-Frifeldt S; Lindebjerg J; Rafaelsen SR; Jensen LH; Jakobsen A; Sørensen FB
Acta Oncol; 2018 Apr; 57(4):528-533. PubMed ID: 28980848
[TBL] [Abstract][Full Text] [Related]
26. A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer.
Yochum ZA; Cades J; Mazzacurati L; Neumann NM; Khetarpal SK; Chatterjee S; Wang H; Attar MA; Huang EH; Chatley SN; Nugent K; Somasundaram A; Engh JA; Ewald AJ; Cho YJ; Rudin CM; Tran PT; Burns TF
Mol Cancer Res; 2017 Dec; 15(12):1764-1776. PubMed ID: 28851812
[TBL] [Abstract][Full Text] [Related]
27. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer.
Isella C; Brundu F; Bellomo SE; Galimi F; Zanella E; Porporato R; Petti C; Fiori A; Orzan F; Senetta R; Boccaccio C; Ficarra E; Marchionni L; Trusolino L; Medico E; Bertotti A
Nat Commun; 2017 May; 8():15107. PubMed ID: 28561063
[TBL] [Abstract][Full Text] [Related]
28. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.
Lugli A; Kirsch R; Ajioka Y; Bosman F; Cathomas G; Dawson H; El Zimaity H; Fléjou JF; Hansen TP; Hartmann A; Kakar S; Langner C; Nagtegaal I; Puppa G; Riddell R; Ristimäki A; Sheahan K; Smyrk T; Sugihara K; Terris B; Ueno H; Vieth M; Zlobec I; Quirke P
Mod Pathol; 2017 Sep; 30(9):1299-1311. PubMed ID: 28548122
[TBL] [Abstract][Full Text] [Related]
29. A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling.
Yeakley JM; Shepard PJ; Goyena DE; VanSteenhouse HC; McComb JD; Seligmann BE
PLoS One; 2017; 12(5):e0178302. PubMed ID: 28542535
[TBL] [Abstract][Full Text] [Related]
30. Colorectal cancer subtypes: Translation to routine clinical pathology.
Roseweir AK; McMillan DC; Horgan PG; Edwards J
Cancer Treat Rev; 2017 Jun; 57():1-7. PubMed ID: 28505475
[TBL] [Abstract][Full Text] [Related]
31. Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer.
Park JH; van Wyk H; Roxburgh CSD; Horgan PG; Edwards J; McMillan DC
Br J Cancer; 2017 May; 116(11):1444-1450. PubMed ID: 28427085
[TBL] [Abstract][Full Text] [Related]
32. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.
Dienstmann R; Vermeulen L; Guinney J; Kopetz S; Tejpar S; Tabernero J
Nat Rev Cancer; 2017 Mar; 17(4):268. PubMed ID: 28332502
[No Abstract] [Full Text] [Related]
33. Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer.
Park JH; McMillan DC; Edwards J; Horgan PG; Roxburgh CS
Oncoimmunology; 2016 Mar; 5(3):e1098801. PubMed ID: 27141369
[TBL] [Abstract][Full Text] [Related]
34. The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review.
van Wyk HC; Park J; Roxburgh C; Horgan P; Foulis A; McMillan DC
Cancer Treat Rev; 2015 Feb; 41(2):151-9. PubMed ID: 25549950
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer.
Park JH; McMillan DC; Powell AG; Richards CH; Horgan PG; Edwards J; Roxburgh CS
Clin Cancer Res; 2015 Feb; 21(4):882-8. PubMed ID: 25473000
[TBL] [Abstract][Full Text] [Related]
36. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
Park JH; Richards CH; McMillan DC; Horgan PG; Roxburgh CSD
Ann Oncol; 2014 Mar; 25(3):644-651. PubMed ID: 24458470
[TBL] [Abstract][Full Text] [Related]
37. Detailed analysis of inflammatory cell infiltration in colorectal cancer.
Väyrynen JP; Tuomisto A; Klintrup K; Mäkelä J; Karttunen TJ; Mäkinen MJ
Br J Cancer; 2013 Oct; 109(7):1839-47. PubMed ID: 24008661
[TBL] [Abstract][Full Text] [Related]
38. Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
Saif MW
Cancer Manag Res; 2013; 5():103-15. PubMed ID: 23807861
[TBL] [Abstract][Full Text] [Related]
39. STAR: ultrafast universal RNA-seq aligner.
Dobin A; Davis CA; Schlesinger F; Drenkow J; Zaleski C; Jha S; Batut P; Chaisson M; Gingeras TR
Bioinformatics; 2013 Jan; 29(1):15-21. PubMed ID: 23104886
[TBL] [Abstract][Full Text] [Related]
40. Cancer classification using the Immunoscore: a worldwide task force.
Galon J; Pagès F; Marincola FM; Angell HK; Thurin M; Lugli A; Zlobec I; Berger A; Bifulco C; Botti G; Tatangelo F; Britten CM; Kreiter S; Chouchane L; Delrio P; Arndt H; Asslaber M; Maio M; Masucci GV; Mihm M; Vidal-Vanaclocha F; Allison JP; Gnjatic S; Hakansson L; Huber C; Singh-Jasuja H; Ottensmeier C; Zwierzina H; Laghi L; Grizzi F; Ohashi PS; Shaw PA; Clarke BA; Wouters BG; Kawakami Y; Hazama S; Okuno K; Wang E; O'Donnell-Tormey J; Lagorce C; Pawelec G; Nishimura MI; Hawkins R; Lapointe R; Lundqvist A; Khleif SN; Ogino S; Gibbs P; Waring P; Sato N; Torigoe T; Itoh K; Patel PS; Shukla SN; Palmqvist R; Nagtegaal ID; Wang Y; D'Arrigo C; Kopetz S; Sinicrope FA; Trinchieri G; Gajewski TF; Ascierto PA; Fox BA
J Transl Med; 2012 Oct; 10():205. PubMed ID: 23034130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
